金城医药：子公司收到化学原料药上市申请批准通知书

Core Viewpoint - The company announced that its wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the marketing of Erythromycin Lactobionate in the domestic market, which will enhance the company's product line and market competitiveness in the chemical raw materials sector [1] Group 1 - The approval allows for the production and sale of Erythromycin Lactobionate in the domestic market [1] - This development is expected to enrich the company's product offerings [1] - The move is anticipated to improve the company's competitiveness in the chemical raw materials industry [1] Group 2 - The sales of the drug are subject to uncertainties due to national policies and changes in the market environment [1]